Evidence map›Paper›PMID 35303528›Full record

ArticleEnvironment international2022

Associations between persistent organic pollutants and type 1 diabetes in youth.

Sophie E Bresson, Scott Isom, Elizabeth T Jensen, Sandra Huber, Youssef Oulhote, Joseph Rigdon, James Lovato, Angela D Liese, Catherine Pihoker, Dana Dabelea and 2 more

Open access · goldAbstract read
In one paragraph

Article in Environment international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Sophie E BressonDepartment of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
Scott IsomWake Forest School of Medicine, Winston-Salem, NC, USA.
Elizabeth T JensenWake Forest School of Medicine, Winston-Salem, NC, USA.
Sandra HuberDepartment of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway.
Youssef OulhoteDepartment of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA.
Joseph RigdonWake Forest School of Medicine, Winston-Salem, NC, USA.
James LovatoWake Forest School of Medicine, Winston-Salem, NC, USA.
Angela D LieseDepartment of Epidemiology and Biostatistics, Arnold School of Public Health, SC, USA.
Catherine PihokerDepartment of Pediatrics, University of Washington, Seattle, WA, USA.
Dana DabeleaLifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center and Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Shelley EhrlichDivision of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical center, Cincinnati, OH, USA; Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Jérôme RuzzinDepartment of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: jerome.ruzzin@medisin.uio.no.
Wake Forest University · USUniversity of Oslo · NOColorado School of Public Health · USUniversity Hospital of North Norway · NOUniversity of Cincinnati Medical Center · USUniversity of Massachusetts Amherst · USUniversity of Washington · US

Funding

Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI MEINZEN-DERR, JAREEN, STRAWN, JEFFREY ROBERT · 2015 to 2024
$37.5M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
Limited Competition for the Continuation of the SEARCH for Diabetes in Youth Cohort Study (UC4)SEARCH for Diabetes in Youth Cohort StudyUC4DK108173 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DAGOSTINO, RALPH B. · 2015 to 2016
$14.8M
UCHSC DIABETES ENDOCRINOLOGY RESEARCH CENTERP30DK057516 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HUTTON, JOHN C · 2000 to 2010
$14.0M
Cincinnati Center for Clinical and Translational Sciences and TrainingUL1TR000077 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., TSEVAT, JOEL · 2012 to 2014
$9.9M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR000062 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2012 to 2014
$9.4M
SEARCH for Diabetes in Youth Coordinating CenterU01DP000250 · DP · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BELL, RONNY A · 2005 to 2009
$4.8M
Population-based Diabetes Youth RegistryU18DP006131 · DP · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2015 to 2019
$3.8M
SEARCH For Diabetes in Youth, Phase 3: Cohort Study-Carolina CenterU18DP002708 · DP · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MAYER-DAVIS, ELIZABETH J · 2010 to 2014
$3.6M
SEARCH for Diabetes in Youth 2: Colorado CenterU01DP000247 · DP · UNIVERSITY OF COLORADO DENVER · PI DABELEA, DANA · 2005 to 2009
$3.6M
SEARCH for Diabetes in Youth 2: South Carolina CenterU01DP000254 · DP · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MAYER-DAVIS, ELIZABETH J · 2005 to 2009
$3.5M
EPA EP-C-15-002HSRD VA HIR 10-001NCATS NIH HHS UL1 TR000062NCATS NIH HHS UL1 TR000077NCATS NIH HHS UL1 TR000154NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR001425NCCDPHP CDC HHS U01 DP000244NCCDPHP CDC HHS U01 DP000246NCCDPHP CDC HHS U01 DP000247NCCDPHP CDC HHS U01 DP000248NCCDPHP CDC HHS U01 DP000250NCCDPHP CDC HHS U01 DP000254NCCDPHP CDC HHS U18 DP002708NCCDPHP CDC HHS U18 DP002709NCCDPHP CDC HHS U18 DP002710NCCDPHP CDC HHS U18 DP002714NCCDPHP CDC HHS U18 DP006131NCCDPHP CDC HHS U18 DP006133NCCDPHP CDC HHS U18 DP006134NCCDPHP CDC HHS U18 DP006136NCCDPHP CDC HHS U18 DP006138NCCDPHP CDC HHS U18 DP006139NIDDK NIH HHS P30 DK057516NIDDK NIH HHS R01 DK127208NIDDK NIH HHS UC4 DK108173
6 · The paper itself

Abstract

backgroundDiabetes affects millions of people worldwide with a continued increase in incidence occurring within the pediatric population. The potential contribution of persistent organic pollutants (POPs) to diabetes in youth remains poorly known, especially regarding type 1 diabetes (T1D), generally the most prevalent form of diabetes in youth.

objectivesWe investigated the associations between POPs and T1D in youth and studied the impacts of POPs on pancreatic β-cell function and viability in vitro.

methodsWe used data and plasma samples from the SEARCH for Diabetes in Youth Case Control Study (SEARCH-CC). Participants were categorized as Controls, T1D with normal insulin sensitivity (T1D/IS), and T1D with insulin resistance (T1D/IR). We assessed plasma concentrations of polychlorinated biphenyls (PCBs) and organochlorine pesticides and estimated the odds of T1D through multivariable logistic regression. In addition, we performed in vitro experiments with the INS-1E pancreatic β-cells. Cells were treated with PCB-153 or p,p'-DDE at environmentally relevant doses. We measured insulin production and secretion and assessed the mRNA expression of key regulators involved in insulin synthesis (Ins1, Ins2, Pdx1, Mafa, Pcsk1/3, and Pcsk2), glucose sensing (Slc2a2 and Gck), and insulin secretion (Abcc8, Kcnj11, Cacna1d, Cacna1b, Stx1a, Snap25, and Sytl4). Finally, we assessed the effects of PCB-153 and p,p'-DDE on β-cell viability.

resultsAmong 442 youths, 112 were controls, 182 were classified with T1D/IS and 148 with T1D/IR. The odds ratios (OR) of T1D/IS versus controls were statistically significant for p,p'-DDE (OR 2.0, 95% confidence interval (CI) 1.0, 3.8 and 2.4, 95% CI 1.2, 5.0 for 2nd and 3rd tertiles, respectively), trans-nonachlor (OR 2.5, 95% CI 1.3, 5.0 and OR 2.3, 95% CI 1.1, 5.1 for 2nd and 3rd tertiles, respectively), and PCB-153 (OR 2.3, 95% CI 1.1, 4.6 for 3rd tertile). However, these associations were not observed in participants with T1D/IR. At an experimental level, treatment with p,p'-DDE or PCB-153, at concentrations ranging from 1 × 10

conclusionThese results support a potential role of POPs in T1D etiology and demonstrate a high sensitivity of pancreatic β-cells to POPs.

Indexed as

Diabetes Mellitus, Type 1Environmental PollutantsHydrocarbons, ChlorinatedInsulin ResistancePesticidesPolychlorinated BiphenylsAdolescentCase-Control StudiesChildDichlorodiphenyl DichloroethyleneGlucoseHumansInsulinPersistent Organic PollutantsRNA, MessengerDichlorodiphenyl DichloroethyleneEnvironmental PollutantsGlucoseHydrocarbons, ChlorinatedInsulinPersistent Organic PollutantsPesticidesPolychlorinated BiphenylsRNA, MessengerOrganochlorine PesticidesPersistent Organic PollutantsPolychlorinated BiphenylsType 1 DiabetesYouths

Identifiers

PMID35303528
PMCPMC11696922
OpenAlexW4220781346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.